HEALWELL Acquires Control of Mutuo Health Solutions to Build Next Generation of AI-Powered Physician Co-Pilots
HEALWELL AI has acquired a 51% controlling interest in Mutuo Health Solutions for $5.5 million in cash and shares. Mutuo's flagship product, AutoScribe, is an AI-powered platform that transcribes clinician-patient dialogues into structured electronic medical records in real-time using machine learning and natural language processing. Founded in 2018, Mutuo developed AutoScribe through collaboration with the University of Toronto and Unity Health Toronto. HEALWELL plans to integrate AutoScribe with its proprietary AI-enabled clinical decision support co-pilots to create a next-generation suite of physician assistance tools focused on clinical administration automation and decision support.
HEALWELL AI ha acquisito una partecipazione di controllo del 51% in Mutuo Health Solutions per 5,5 milioni di dollari in contante e azioni. Il prodotto di punta di Mutuo, AutoScribe, è una piattaforma supportata da intelligenza artificiale che trascrive in tempo reale i dialoghi tra clinici e pazienti in registrazioni mediche elettroniche strutturate, utilizzando l'apprendimento automatico e l'elaborazione del linguaggio naturale. Fondata nel 2018, Mutuo ha sviluppato AutoScribe attraverso la collaborazione con l'Università di Toronto e Unity Health Toronto. HEALWELL prevede di integrare AutoScribe con i propri co-piloti per il supporto alle decisioni cliniche abilitati all'AI, creando una suite di strumenti per l'assistenza ai medici di nuova generazione focalizzati sull'automazione dell'amministrazione clinica e sul supporto alle decisioni.
HEALWELL AI ha adquirido una participación de control del 51% en Mutuo Health Solutions por 5.5 millones de dólares en efectivo y acciones. El producto insignia de Mutuo, AutoScribe, es una plataforma impulsada por inteligencia artificial que transcribe en tiempo real los diálogos entre clínicos y pacientes en registros médicos electrónicos estructurados, utilizando el aprendizaje automático y el procesamiento del lenguaje natural. Fundada en 2018, Mutuo desarrolló AutoScribe a través de la colaboración con la Universidad de Toronto y Unity Health Toronto. HEALWELL planea integrar AutoScribe con sus copilotos de soporte de decisiones clínicas habilitados por IA para crear un conjunto de herramientas de asistencia médica de nueva generación enfocadas en la automatización de la administración clínica y el soporte a la toma de decisiones.
HEALWELL AI는 Mutuo Health Solutions의 51% 지분을 550만 달러의 현금 및 주식으로 인수했습니다. Mutuo의 대표 제품인 AutoScribe는 AI 기반 플랫폼으로, 임상 의사와 환자 간의 대화를 실시간으로 구조화된 전자 의료 기록으로 전사하며, 머신 러닝과 자연어 처리 기술을 사용합니다. 2018년에 설립된 Mutuo는 토론토 대학교와 Unity Health Toronto와의 협력을 통해 AutoScribe를 개발했습니다. HEALWELL은 AutoScribe를 자사의 AI 지원 임상 결정 지원 코파일럿과 통합하여 임상 관리 자동화와 결정 지원에 중점을 둔 차세대 의사 보조 도구 모음을 만들 계획입니다.
HEALWELL AI a acquis une participation de contrôle de 51 % dans Mutuo Health Solutions pour 5,5 millions de dollars en espèces et en actions. Le produit phare de Mutuo, AutoScribe, est une plateforme alimentée par l'intelligence artificielle qui transcrit en temps réel les dialogues entre cliniciens et patients en dossiers médicaux électroniques structurés, en utilisant l'apprentissage automatique et le traitement du langage naturel. Fondée en 2018, Mutuo a développé AutoScribe en collaboration avec l'Université de Toronto et Unity Health Toronto. HEALWELL prévoit d'intégrer AutoScribe avec ses copilotes de support à la décision clinique propulsés par l'IA pour créer une suite d'outils d'assistance aux médecins de nouvelle génération axée sur l'automatisation de l'administration clinique et le support à la décision.
HEALWELL AI hat eine kontrollierende Beteiligung von 51% an Mutuo Health Solutions für 5,5 Millionen US-Dollar in bar und Aktien erworben. Das Flaggschiffprodukt von Mutuo, AutoScribe, ist eine KI-gestützte Plattform, die Dialoge zwischen Kliniken und Patienten in Echtzeit in strukturierte elektronische Patientenakten umschreibt, indem maschinelles Lernen und natürliche Sprachverarbeitung verwendet werden. Mutuo wurde 2018 gegründet und entwickelte AutoScribe in Zusammenarbeit mit der University of Toronto und Unity Health Toronto. HEALWELL plant, AutoScribe mit seinen eigenen KI-gestützten klinischen Entscheidungsunterstützungssystemen zu integrieren, um eine nächste Generation von Hilfstools für Ärzte zu schaffen, die sich auf die Automatisierung klinischer Verwaltung und Entscheidungsunterstützung konzentrieren.
- Strategic acquisition of 51% controlling stake in Mutuo Health Solutions for $5.5M
- Integration of AutoScribe platform enhances HEALWELL's AI technology portfolio
- Expansion into real-time medical transcription and EMR automation market
- Synergistic combination with existing clinical decision support co-pilots
- Cash and share expenditure of $5.5M for acquisition
- HEALWELL has acquired a majority controlling interest in Mutuo Health Solutions, a Toronto-based medical artificial intelligence company focused on developing predictive clinical AI technology.
- Mutuo Health's AutoScribe platform is an advanced AI-powered ambient scribe solution that transcribes clinician-patient interactions into high-quality electronic medical records in real time using natural language processing and machine learning technology.
- AutoScribe's speech recognition capabilities, designed with a robust patient privacy framework, allows healthcare providers to focus on patient care, significantly reduce administrative burden and enhance care delivery.
- HEALWELL plans to combine AutoScribe with its proprietary AI enabled decision support co-pilots, creating a next generation suite of AI powered physician co-pilots that significantly elevate physician efficiency.
Toronto, Ontario--(Newsfile Corp. - December 3, 2024) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to announce that it has acquired a
Founded in 2018 by a team of AI researchers and healthcare professionals, including a family doctor who experienced first-hand the challenges of documentation burnout, Mutuo's commercializing of AutoScribe was initiated as part of a unique collaboration between the University of Toronto and Unity Health Toronto. The platform sets itself apart with its focus on precision, security, and integration within Canadian healthcare, making every patient interaction an opportunity to optimize care. By capturing and structuring patient data in real time, AutoScribe enables healthcare providers to focus on patient care, enhancing clinical accuracy and operational efficiency.
Mutuo's AutoScribe platform transcends traditional medical dictation by utilizing advanced AI-driven transcription and predictive capabilities, continuously improving through its machine learning framework. HEALWELL's acquisition of a controlling stake in Mutuo will deepen the Company's technology portfolio and expand its offering of AI-driven healthcare solutions. HEALWELL plans to integrate AutoScribe into its proprietary best-in-class AI-enabled clinical decision support co-pilots; creating a next generation suite of physician co-pilots that will provide highly integrated best-in-class clinical administration automation and clinical decision support. By integrating AutoScribe's capabilities, HEALWELL will be able to provide advanced, customizable digital assistance to healthcare providers, particularly addressing the growing need for documentation and electronic medical record (EMR) automation in clinics and hospitals. The acquisition helps to further position HEALWELL as a leader in predictive AI solutions designed to streamline clinical workflows, improve patient care, and assist providers with advanced clinical decision support.
Dr. Alexander Dobranowski, CEO of HEALWELL, commented, "We are excited to welcome Mutuo and their remarkable AutoScribe technology to HEALWELL. This acquisition is another step forward in our mission to provide healthcare professionals with the most advanced AI tools to optimize patient care and ultimately help with the earlier identification and detection of disease. AutoScribe's unique real-time transcription capabilities, combined with its predictive AI framework, will significantly enhance how clinicians manage patient data, allowing them to focus more on patient-centered care. We look forward to working with Mutuo's team of talented researchers and medical professionals to further scale this technology."
Dr. Noah Crampton, CEO of Mutuo Health Solutions, commented, "Our team at Mutuo is thrilled to join forces with HEALWELL to bring AutoScribe to more healthcare providers across Canada and beyond. This partnership allows us to leverage HEALWELL's expertise and vast network to accelerate our mission of reducing administrative fatigue for doctors while improving the quality of care that patients receive. We are eager to see the positive impact this collaboration will have on the healthcare community."
Dr. Alexander Dobranowski
Chief Executive Officer
HEALWELL AI Inc.
About HEALWELL
HEALWELL is a healthcare artificial intelligence company focused on preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTC Exchange under the symbol "HWAIF". To learn more about HEALWELL, please visit https://healwell.ai/.
Forward-Looking Statements
Certain statements in this press release, constitute "forward-looking information" and "forward looking statements" (collectively, "forward looking statements") within the meaning of applicable Canadian securities laws and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements in this press release include statements with respect to, among other things, Healwell's plan to integrate Mutuo's AutoScribe with its own AI-enabled clinical co-pilots; into its own future product and service offerings; the potential benefits of Mutuo's product and service offerings; and potential synergies between Mutuo and the Company. Forward-looking statements are often, but not always, identified by words or phrases such as "opportunity", "potential", "improve", "expect", "create", "plan", "enable", "position" or variations of such words and phrases or statements that certain future conditions, actions, events or results "will", "may", "could", "would", "should", "might" or "can" be taken, occur or be achieved, or the negative of any of these terms . Forward-looking statements are necessarily based upon management's perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by HEALWELL as of the date of such statements, are outside of HEALWELL's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward-looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: HEALWELL's ability to successfully integrate the Mutuo's business into its own; HEALWELL's ability to leverage artificial intelligence, data management and other services and expertise to expand and accelerate Mutuo's service offerings; trends in customer growth; HEALWELL's ability to develop new technologies and the timelines on which they can be developed; new technologies functioning as expected; customers adopting and using new technologies and services as expected; the need to develop increasingly innovative products and services; competition in the industry; the stability of general economic and market conditions; HEALWELL's ability to comply with applicable laws and regulations; HEALWELL's continued compliance with third party intellectual property rights; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.
Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled "Risk Factors" in HEALWELL's most recent annual information form dated April 1, 2024, which is available under HEALWELL's SEDAR+ profile at www.sedarplus.com. The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.
For more information:
Pardeep S. Sangha
Investor Relations, HEALWELL AI Inc.
Phone: 604-572-6392
ir@healwell.ai
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232286
FAQ
What is the value of HEALWELL's acquisition of Mutuo Health Solutions (HWAIF)?
What is AutoScribe platform acquired by HEALWELL (HWAIF)?
How will HEALWELL (HWAIF) integrate the Mutuo Health acquisition?
When was Mutuo Health Solutions founded before HEALWELL's acquisition (HWAIF)?
